Phase I Study of ARX788 in HER2-Positive Metastatic Breast Cancer: Safety and Efficacy

Abstract Purpose: ARX788 is a novel antibody-drug conjugate (ADC) comprised of an anti-HER2 mAb and a potent tubulin inhibitor payload AS269 that is site-specifically conjugated to the antibody via a nonnatural amino acid incorporated into the antibo...